Voya Investment Management LLC Has $14.62 Million Stock Holdings in TG Therapeutics, Inc. $TGTX

Voya Investment Management LLC reduced its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 404,727 shares of the biopharmaceutical company’s stock after selling 18,054 shares during the quarter. Voya Investment Management LLC’s holdings in TG Therapeutics were worth $14,621,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in TGTX. Ameritas Advisory Services LLC bought a new position in TG Therapeutics in the 2nd quarter valued at about $25,000. Johnson Financial Group Inc. purchased a new stake in shares of TG Therapeutics in the second quarter worth approximately $25,000. SVB Wealth LLC purchased a new stake in shares of TG Therapeutics in the first quarter worth approximately $37,000. Private Wealth Asset Management LLC bought a new position in shares of TG Therapeutics in the second quarter valued at approximately $37,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 573 shares during the last quarter. 58.58% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. B. Riley upgraded shares of TG Therapeutics to a “strong-buy” rating in a report on Tuesday, November 4th. HC Wainwright began coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective for the company. Weiss Ratings restated a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 15th. Finally, Wall Street Zen raised TG Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, December 14th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $50.25.

TG Therapeutics Stock Up 0.5%

TGTX opened at $31.12 on Tuesday. TG Therapeutics, Inc. has a twelve month low of $25.28 and a twelve month high of $46.48. The company’s 50-day moving average price is $32.38 and its two-hundred day moving average price is $33.42. The stock has a market cap of $4.94 billion, a price-to-earnings ratio of 11.19 and a beta of 2.01. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $2.19. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The company had revenue of $161.71 million during the quarter, compared to analyst estimates of $152.12 million. During the same quarter last year, the business posted $0.02 EPS. TG Therapeutics’s quarterly revenue was up 92.7% compared to the same quarter last year. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Buying and Selling at TG Therapeutics

In other news, Director Yann Echelard sold 5,000 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $32.57, for a total transaction of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares in the company, valued at approximately $7,289,687.12. This represents a 2.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 10.64% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.